Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients.

LHA-ID
7RWQHJGEGA-2
Summary

Male sex is associated with unfavourable pharmacokinetics and prognosis in elderly patients with diffuse large B-cell lymphoma (DLBCL). We investigated higher rituximab doses for elderly male DLBCL patients. Elderly patients (61-80 years) received 6 cycles CHOP-14 (cyclophosphamide, doxorubicin, vincristine and prednisone at 14-day intervals) and were randomized to 8 cycles rituximab (males 500 mg/m2 , females 375 mg/m2 ) every 2 weeks or according to an upfront dose-dense schedule.

Abstract
Male sex is associated with unfavourable pharmacokinetics and prognosis in elderly patients with diffuse large B-cell lymphoma (DLBCL). We investigated higher rituximab doses for elderly male DLBCL patients. Elderly patients (61-80 years) received 6 cycles CHOP-14 (cyclophosphamide, doxorubicin, vincristine and prednisone at 14-day intervals) and were randomized to 8 cycles rituximab (males 500 mg/m
DOI
10.1111/bjh.14860
Publication Date
Journal
British journal of haematology
Journal Volume
179
Journal Number
3
Corresponding Author
Prof. Dr. G. Held
Corresponding Author Institution

Studiensekretariat Homburg; Universität des Saarlandes; 66421 Homburg

Corresponding Author email
Publication Type
Human Disease Ontology Concept